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Summary
 
The sensitivity of primary splenic B cells to Fas-mediated apoptosis is modulated in a receptor-
specific fashion. Here we used a differential display strategy to detect cDNAs present in B cells
rendered Fas resistant but absent in those rendered Fas sensitive. This led to the cloning and
characterization of a novel 1.2-kb gene that encodes a Fas
 
 
 
apoptosis inhibitory molecule
(FAIM). 
 
faim
 
-transfected BAL-17 B lymphoma cells were less sensitive by half or more to Fas-
mediated apoptosis than were vector-transfected controls, using Fas ligand–bearing T cells or a
cytotoxic anti-Fas antibody to trigger Fas, and this was associated with inhibition of Fas-
induced poly-ADP ribose polymerase (PARP) cleavage. In primary B cells, the time course of
 
faim
 
 mRNA and FAIM protein expression correlated with the induction of Fas resistance by
surface (s)Ig engagement. Thus, FAIM is an inducible effector molecule that mediates Fas resis-
tance produced by sIg engagement in B cells. However, 
 
faim
 
 is broadly expressed in various tissues
and the 
 
faim
 
 sequence is highly conserved evolutionarily, suggesting that its role extends beyond
lymphocyte homeostasis. As FAIM has no significant regions of homology to other gene products
that modulate Fas killing, it appears to represent a distinct, new class of antiapoptotic protein.
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T
 
he Fas/Fas ligand (FasL)
 
1
 
 system is one of an expand-
ing family of receptor–ligand pairs involved in cell fate
determination in a variety of cell types, notably including
those of lymphoid origin (1). Fas engagement initiates an
intracellular signaling cascade through oligomerization of
caspase 8, mediated via the adaptor protein FADD, which
contains both death and death effector homologous do-
mains (2). Caspase 8 appears to be the most proximal of
several ICE-like proteases whose sequential activation is re-
sponsible for the apoptotic demise of the cell (3–6). Fas en-
gagement also triggers mitochondrial cytochrome 
 
c
 
 release
that, in conjunction with apoptotic protease-activating fac-
tor (APAF)-1 and dATP, activates caspase 9 and downstream
caspases (7–11). Fas signaling for cell death may be modulated
by several distinct antiapoptotic proteins, which directly bind
Fas, inhibit caspase activity or activation, or modulate mito-
chondrial events (9, 10, 12–21).
We and others have shown that the susceptibility of
primary B cells to Fas-mediated apoptosis is regulated in a
receptor-specific fashion (22–24). Engagement of CD40
upregulates Fas expression and renders B cells sensitive to
Fas-mediated apoptosis, whereas concurrent or sequential
signaling through the B cell antigen receptor induces a state
of Fas resistance (22). Induction of Fas resistance develops
progressively over a period of hours, and depends on macro-
molecular synthesis, suggesting that protection against Fas
killing requires the induction and accumulation of one or
more gene products (reference 25 and our unpublished ob-
servations). Indeed, we recently demonstrated that Bcl-x
 
L
 
expression is upregulated in primary B cells that have been
rendered Fas resistant, and showed that overexpression of
Bcl-x
 
L
 
 diminishes Fas-mediated apoptosis in CD40L-stim-
ulated B cells obtained from transgenic mice (26). How-
ever, a role for other gene products is suggested by three
observations. First, Bcl-x
 
L
 
–overexpressing B cells were not
completely protected from Fas killing (26). Second, treat-
ment of Bcl-x
 
L
 
–overexpressing B cells with anti-Ig pro-
duced additional inhibition of Fas-mediated apoptosis (26).
Third, Bcl-x
 
L 
 
protein appeared in normal B cells after, not
 
1
 
Abbreviations used in this paper:
 
 EST, expressed sequence tag; FAIM, Fas
apoptosis inhibitory molecule; FasL, Fas ligand; HEL, hen egg lysozyme;
PARP, poly-ADP ribose polymerase; sIg, surface Ig. 
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before, the first manifestations of anti-Ig–induced Fas resis-
tance (25, 26). These results raise the possibility that ad-
ditional gene products, induced by surface (s)Ig cross-link-
ing, contribute to Fas resistance. Herein we describe the
use of differential display to elucidate, in an unbiased fash-
ion, inducible factors that modulate susceptibility to Fas-
mediated apoptosis in B cells, and report the identification
of a gene that, when overexpressed in a model B cell line,
reduces Fas sensitivity and thus codes for a Fas apoptosis in-
hibitory molecule termed FAIM.
 
Materials and Methods
 
Mice.
 
Male Balb/cByJ mice at 8–14 wk of age were obtained
from The Jackson Laboratory. Mice were housed at least 1 wk
before experimentation. Mice were cared for and handled at all
times in accordance with the National Institutes of Health and
our institutional guidelines.
 
B Cell Purification.
 
Splenic B cells from 8–12-wk-old naive
Balb/cByJ mice were purified and depleted of T cells and mac-
rophages as previously described (22). RBCs and nonviable cells
were removed by sedimentation over Lympholyte M (Cedarlane
Labs., Canada). The resulting B cells were cultured at 37
 
8
 
C with
5% CO
 
2 
 
in RPMI 1640 medium (BioWhittaker) supplemented
with 5% heat-inactivated fetal bovine serum (Sigma Chemical
Co.), 10 mM Hepes (pH 7.2), 50 
 
m
 
M 2-ME, 2 mM 
 
l
 
-glutamine,
100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin.
 
Differential Display.
 
Total RNA was prepared from primary
murine splenic B cells stimulated with CD40L/CD8
 
a
 
 fusion
protein cross-linked with anti-CD8 antibody (CD40L) for 48 h,
in the absence or presence of F(ab
 
9
 
)
 
2
 
 fragments of polyclonal goat
anti–mouse IgM (anti-Ig) added for the final 6 h of the culture
period, using Phenol/GITC (Sigma Chemical Co.; 27). Reverse
transcription and differential display were performed as previously
described (28) using the RNAImage Kit (GenHunter). Putatively
differentially expressed cDNA fragments were excised from dried
sequencing gels, eluted in dH
 
2
 
O, and reamplified using the same
primer pair originally used in differential display. These fragments
were tested for differential expression by Northern blot analysis;
PCR products confirmed by this assay were subcloned into a TA
cloning vector (Invitrogen). Plasmid DNA from individual clones
was radiolabeled and used to probe additional Northern blots in or-
der to identify the insert responsible for differential expression. Sub-
cloned Northern blot–positive cDNAs were subject to automated
fluorescent DNA sequencing (Applied Biosystems) and analyzed by
comparison to standard sequencing databases in the public domain
(BLAST; National Center for Biotechnology Information).
 
Northern Blotting.
 
Total RNA was prepared from primary
murine splenic B cells using UltraSpec RNA isolation reagent
(Biotecx Laboratories). Purified RNA was electrophoresed on a
1% agarose/formaldehyde gel, transferred to GeneScreen Plus
(NEN) in 10
 
3
 
 SSC and hybridized to a 234-bp radiolabeled
fragment of 
 
faim 
 
generated by PCR, using the primers CTGGA-
TGGCGAGGACCTGAG (5
 
9
 
) and GGTGTCACTGAGTGA-
GCTCTG (3
 
9
 
). Initial Northern probing to confirm differential
expression was performed as above except that differential display
primers were used and the annealing step of PCR was performed
for 2 min at 40
 
8
 
C. Autoradiography was performed using intensi-
fying screens at 
 
2
 
80
 
8
 
C for 1–3 d. A multiple tissue Northern blot
was obtained from OriGene Technologies.
 
cDNA Library Screening.
 
A radiolabeled probe generated as
described above was used to screen a directional murine thymic
cDNA library that was constructed in pBKCMV (Stratagene) and
was provided by Dr. Adam Lerner (Boston University Medical
Center, Boston, MA). Plaque lifts were performed using Protran
membranes (Schleicher and Schuell). A number of individual
clones from among 10
 
6
 
 plaques were sequenced, leading to the
isolation of a full-length clone as determined by an in-frame stop
codon upstream of the start methionine. This clone encodes a
novel 179–amino acid protein as discussed below.
 
Transfection.
 
Mid-log phase BAL-17 B lymphoma cells in
suspension were transfected with 20 
 
m
 
g 
 
faim
 
-containing plasmid
or pBKCMV empty vector (plus 500 
 
m
 
g carrier salmon sperm
DNA) by electroporation at 276 V and 550 
 
m
 
F using a Gene
Pulser apparatus (Bio-Rad). Transfected cells were immediately
plated to prewarmed medium and cultured at 37
 
8
 
C with 5% CO
 
2
 
as above (29). After 2 d, transfected cells were split 1:15 into fresh
medium containing 2 mg/ml G418 (Sigma Chemical Co.) to ob-
tain pools of transfectants. Separately, individual stably transfected
clones were isolated by limiting dilution in medium containing
G418.
 
Fas-mediated Apoptosis.
 
BAL-17 transfectants stimulated for
24 h with CD40L were tested as targets in standard 4-h, lectin-
dependent 
 
51
 
Cr-release assays with AE7 CD4
 
1
 
 Th1 effector cells
at effector/target cell ratios of 0.3:1 to 9:1, as previously described
(22, 25), or with Jo-2 anti-Fas antibody (PharMingen) at 50, 5, or
0.5 ng/ml. Alternatively, nuclei obtained from CD40L-stimu-
lated BAL-17 transfectants were stained with propidium iodide
and the level of subdiploid DNA was determined by flow cytom-
etry, as described (30).
 
PARP Cleavage.
 
B cell protein lysates were resolved by 15%
SDS-PAGE, transferred to Hybond nitrocellulose membranes
(Amersham), and blocked with 5% nonfat dry milk in TBS-Tween
20 (TBS-T) for 1 h at room temperature. Membranes were probed
with anti-PARP antibody 2-C-10 (Calbiochem) at 1:500 in
TBS-T. After washing, blots were incubated with horseradish per-
oxidase–conjugated goat anti–mouse IgG and developed by en-
hanced chemiluminescence (NEN), as previously described (31).
 
Fas Expression.
 
B cells were stained with PE-conjugated Jo-2
Fas-specific antibody or anti-TNP isotype control antibody (Phar-
Mingen) in the presence of 2% normal rabbit serum and 2.4G2
(anti-FcR) antibody, as previously described (32). Relative fluo-
rescence intensity was detected by flow cytometry with a FAC-
Scan
 
®
 
 instrument (Becton Dickinson).
 
FAIM Expression.
 
Two peptides (amino acids 57–68 and
125–138) corresponding to predicted hydrophilic regions of the
FAIM open reading frame (33) were synthesized by Research
Genetics Corp. These peptides contain an NH
 
2
 
-terminal cysteine
followed by an amino-caproic acid. Each peptide (2 mg) was sep-
arately coupled to KLH (Pierce Chemical Co.); the coupled pep-
tides were combined and used to generate anti-FAIM peptide
antibodies in chickens (Aves Labs.). B cell protein lysates were
resolved by 15% SDS-PAGE, transferred to Hybond nitrocellu-
lose membranes (Amersham), and blocked with 10% Blok-Hen
blocking reagent (Aves Labs.) for 1 h at room temperature. The
nitrocellulose filters were then probed with FAIM-specific anti-
bodies diluted 1:1,000 in TBS-T containing 10% Blok-Hen for
1.5 h at room temperature. After washing, blots were incubated
with horseradish peroxidase–conjugated goat anti–chicken IgY
(Aves Labs.) for 1 h and developed by enhanced chemilumines-
cence (NEN) as described (31).
 
Reagents.
 
Affinity purified F(ab
 
9
 
)
 
2
 
 fragments of polyclonal
goat anti–mouse IgM were obtained from Jackson ImmunoRe-
search Labs. and used at 10 
 
m
 
g/ml. Soluble rCD40L was obtained
from transfected J558L cells that secrete a chimeric CD40L/ 
951
 
Schneider et al.
CD8
 
a
 
 fusion protein (34), which was collected and dialyzed
against 25,000 mol wt cut-off dialysis tubing, as previously
described (35). A similarly dialyzed supernatant containing anti-
CD8 antibody from the 53-6-72 hybridoma was used to cross-link
the fusion protein. CD40L and anti-CD8 containing supernatants
were used at final dilutions of 1:10 and 1:80, respectively. G418
was obtained from GIBCO BRL. An expressed sequence tag
(EST) encompassing putative human FAIM was obtained from the
I.M.A.G.E. consortium (36). 
 
51
 
Cr was obtained from NEN.
 
Results
 
In previous work we showed that B cell treatment with
anti-Ig for only the final 1–12 h of a 48-h culture with
CD40L produced a time-dependent increase in Fas resis-
tance that was abrogated by cycloheximide (25). Additional
experiments demonstrated that the induction of Fas resis-
tance in CD40L-stimulated B cells by anti-Ig treatment for
6 h was completely blocked by the addition of actinomy-
cin D (data not shown). These results strongly suggest that
transcriptional activation and gene expression are required
for the receptor-specific induction of the Fas-resistant state.
For this reason, genes that oppose Fas-mediated apoptosis
might be captured by identifying transcripts expressed
uniquely in Fas-resistant B cells.
 
Differential Display Detects Transcripts Specific for B Cells
Rendered Fas Resistant.
 
To identify genes expressed coor-
dinately with the induction of Fas resistance, we used a dif-
ferential display strategy (28). RNA was extracted from B
cells stimulated with CD40L alone for 48 h (Fas-sensitive)
and from B cells stimulated with CD40L (for 48 h) plus
anti-IgM for the final 6 h of culture (Fas-resistant), and
was reverse transcribed. Application of arbitrary decameric
primer pairs to these cDNA populations permitted repro-
ducible amplification of a number of transcripts present in
Fas-resistant B cells but absent in their Fas-sensitive coun-
terparts. These amplified gene fragments were excised and
used as probes in Northern blots of RNA obtained from
Fas-sensitive and Fas-resistant primary B cells to confirm
differential expression (Fig. 1 A). Of 40 such fragments, 8
failed to reamplify. Of the remaining 32, 8 displayed differ-
ential expression by Northern blot analysis. One of these
recognized an 
 
z
 
1.2-kb transcript on Northern blot (Fig. 1
A) that was widely expressed in multiple tissues, with the
highest levels present in murine brain, thymus, kidney, and
spleen (Fig. 1 B). This transcript was chosen for further
analysis.
 
A Differentially Expressed Gene Encodes a Novel Protein.
 
Using a radiolabeled probe generated by PCR, a murine
thymic cDNA library was screened and the DNA from
positive plaques was sequenced. A number of overlapping
clones were identified whose consensus sequence was 
 
z
 
1.2
kb, consistent with the expression data described above.
Subsequently a full-length clone was identified that con-
tained an in-frame STOP codon upstream of the START
methionine, and possessed, in the 3
 
9
 
 UTR, an RNA insta-
bility motif, polyA
 
1
 
 consensus motifs and a polyA
 
1
 
 tail
(37). This cDNA appeared to encode a novel 179–amino
acid open reading frame (Fig. 2). Structural analysis pre-
dicted a 
 
b
 
-strand–rich, stable, soluble protein with a slightly
acidic pI (pH 5.4). No substantial regions of homology
with any other sequence are present.
 
A Full Length Clone Functions as a Fas Apoptosis Inhibitory
Molecule (FAIM).
 
To determine the capacity of the isolated
cDNA clone to produce resistance to Fas-mediated apop-
tosis, BAL-17 murine B lymphoma cells were transfected
with the pBKCMV expression vector. BAL-17 cells were
chosen because their activation responses mimic primary B
cells in a variety of ways and they are readily transfectable
(38–40). Like primary B cells, unstimulated BAL-17 B cells
express little Fas, but treatment with CD40L induces Fas
expression and sensitivity to Fas-mediated apoptosis (data
not shown). After electroporation, pools of BAL-17 B cells
stably transfected with either full-length cDNA or empty
vector were selected in G418 for 2 wk. These two popula-
tions differed in their susceptibility to Fas killing induced
by FasL-bearing Th1 effector cells: at each effector/target
Figure 1. Expression of a gene
identified by differential display. (A)
Northern blot showing differential
expression of an RNA species in
Fas-sensitive primary B cells stimu-
lated by CD40L alone (2) and in
Fas-resistant B cells stimulated by
CD40L plus anti-Ig (1), as de-
scribed in Materials and Methods.
Arrows indicate the location of ri-
bosomal RNA. (B) Northern blot
showing expression of an RNA
species in various murine tissues, as
indicated in figure.
Figure 2. Predicted amino acid sequence of a gene, differentially ex-
pressed in Fas-sensitive and Fas-resistant B cells, that encodes a Fas apop-
tosis inhibitory molecule (FAIM), and comparison of FAIM protein se-
quences from mouse, human, and C. elegans. Protein sequences were
predicted from nucleotide sequences. Amino acids are numbered to the
left and right of each sequence. Identical amino acids are shaded. Gaps in-
corporated into the C. elegans sequence to optimize alignment are indi-
cated by dots. Nucleotide sequence data are available from EMBL/Gen-
Bank/DDBJ under accession No. AF130367. 
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cell ratio tested, specific lysis of cDNA-transfected BAL-17
B cells, detected by Cr-release assay, was reduced by half or
more in comparison to cells transfected with vector alone
(Fig. 3 A), despite equivalent levels of surface Fas expres-
sion (data not shown). These results suggest a level of pro-
tection of ninefold or more, in terms of the effector/target
ratio required to produce equivalent levels of apoptosis in
 
faim
 
- and vector-transfected BAL-17 B cells. The reduction
in Fas killing was also apparent when cytotoxicity was in-
duced by lytic Jo-2 anti-Fas antibody (data not shown). In
addition, stably transfected clones were isolated by limiting
dilution and tested for susceptibility to Fas killing. The results
obtained with individual clones completely mimicked those
obtained with G418-resistant pools in that Fas-mediated ap-
optosis (produced by Jo-2) was reduced by one-half to two-
thirds in stably transfected cDNA-expressing BAL-17 B cells
in comparison to BAL-17 cells transfected with empty vec-
tor, as detected by propidium iodide staining for subdiploid
DNA (Fig. 3 B). These data indicate that the novel cDNA
transcript initially identified in inducibly Fas-resistant B cells
codes for a Fas apoptosis inhibitory molecule (FAIM) that
counteracts Fas signaling for cell death when overexpressed.
 
FAIM Expression Blocks PARP Cleavage.
 
To character-
ize the nature of the FAIM-induced block in Fas signaling
for cell death, the fate of PARP, a terminal caspase cleav-
age product, was examined by Western blot of size-separated
whole cell extracts (41). Proteolytic fragments of PARP
were readily detected when vector-transfected BAL-17 B
cells were treated for 40 min with Jo-2 anti-Fas antibody. In
contrast, there was little or no PARP cleavage in 
 
faim
 
-trans-
fected BAL-17 B cells up to 60 min after anti-Fas treatment
(Fig. 3 C). Thus, FAIM blocks Fas apoptosis at a step proxi-
mal to the cleavage of the caspase substrate, PARP.
As a control for these experiments, FAIM expression in
 
faim
 
- and vector-transfected BAL-17 B cells was deter-
mined by Western blotting with polyclonal anti-FAIM an-
tibody. Antibody was prepared by immunizing chickens
with two relatively hydrophilic peptides derived from the
FAIM sequence (amino acids 57–68, DGKEEIRREWMF;
and 125–138, RLDGEDLRVVLEKD) coupled to KLH;
the resultant antibody (purified from the IgY fraction of
egg yolks) specifically recognized a protein of the expected
size, 
 
z
 
20 kD, on Western blot, whereas pre-immune IgY
did not. Using this antibody, the expression of FAIM pro-
tein was found to be much increased in 
 
faim
 
-transfected, as
opposed to vector-transfected, BAL-17 B cells (Fig. 3 C).
 
faim Expression Correlates Well with Inducible Fas Resis-
tance.
 
To further evaluate the association between FAIM
expression and inducible Fas resistance, primary B cells were
studied by Northern and Western blotting after stimulation
with CD40L and anti-Ig. CD40L stimulation alone, which
induces Fas expression and Fas sensitivity, elicited little or
no increase in 
 
faim 
 
expression over the low basal level
present in unstimulated B cells. However, addition of anti-
IgM, which induces Fas resistance, to CD40L-stimulated B
cells produced a marked, time-dependent increase in 
 
faim
Figure 3. Modulation of Fas-
mediated apoptosis in BAL-17 B
cells transfected with faim. (A)
Lysis of CD40L-stimulated faim-
(black bars) and vector- (gray
bars) transfected BAL-17 cells
produced by FasL-bearing CD41 Th1 AE7 effector cells at various effector/target cell ratios, as indicated. Levels of specific
target cell lysis were assessed by 51Cr-release assay. One of five comparable experiments is shown. (B) DNA fragmentation
in CD40L-stimulated faim- and vector-transfected BAL-17 cells produced by Jo-2 lytic anti-Fas antibody, as indicated.
Relative levels of subdiploid DNA were assessed by propidium iodide staining and flow cytometric analysis. One of four
comparable experiments is shown. (C) PARP cleavage in CD40L-stimulated faim- and vector-transfected BAL-17 cells
produced by treatment by Jo-2 anti-Fas antibody for 20–60 min as indicated. PARP was detected by Western blotting
size-separated whole cell lysates. Arrows indicate native PARP and cleaved PARP. One of three comparable experiments
is shown. (D) FAIM expression in faim- and vector-transfected BAL-17 cells. FAIM was detected by Western blotting
size-separated whole cell lysates. An arrow indicates the location of FAIM protein. One of three comparable experiments
is shown. 
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mRNA, beginning at 1 h and reaching a maximum after 6 h
of anti-Ig treatment (Fig. 4 A). Similar results were ob-
tained when the expression of FAIM protein was moni-
tored. FAIM was absent in unstimulated B cells and B cells
stimulated for 48 h with CD40L alone; however, addition
of anti-IgM to CD40L-stimulated B cells produced a marked
increase in FAIM protein, first seen after 18 h of anti-Ig
treatment (Fig. 4 B). In some experiments FAIM protein
expression was detected after 6 h of anti-Ig treatment (data
not shown).
The correlation between sIg-induced FAIM expression
and Fas resistance was tested further by examining tolerant,
autoreactive B cells obtained from double transgenic, anti–
hen egg lysozyme (HEL)/HEL mice. In these B cells, in
vitro studies showed that specific antigen (soluble [s]HEL) is
an insufficient stimulus to produce Fas resistance, whereas
Fas resistance is induced by more extensive sIg cross-linking
with anti-Ig (42). In keeping with this, sHEL failed to induce
upregulation of FAIM protein expression in B cells drawn
from double transgenic anti-HEL/HEL mice, whereas FAIM
protein was induced by anti-Ig in these B cells (Fig. 4 C). In
this situation, as with anti-Ig–treated B cells from normal
mice, above, induction of FAIM expression correlates with
production of Fas resistance.
 
faim Is Evolutionarily Conserved.
 
To evaluate the possi-
bility that 
 
faim
 
 is phylogenetically conserved, public data-
bases were searched for evidence of similar genes in other
species. Human 
 
faim
 
 was obtained by identifying a consen-
sus sequence from overlapping human ESTs with homol-
ogy to mouse 
 
faim
 
, followed by sequencing of a single EST
clone that completely spanned putative human 
 
faim
 
 (36).
The consensus/EST sequence was used to predict an amino
acid sequence, which showed human FAIM to be 90%
identical to the predicted amino acid sequence of mouse
FAIM (see Fig. 2). These results are complemented by
Southern blot analysis of genomic DNA showing hybrid-
ization by a mouse 
 
faim
 
 probe to all mammalian species
tested (human, monkey, rat, mouse, dog, cow, and rabbit;
data not shown).
 
C
 
.
 
 elegans
 
 FAIM was obtained by amplifying cDNA with
primers based on the predicted exon structure of a random
genomic sequence of unknown function, and then se-
quencing the resultant DNA. The predicted amino acid
sequence of this 
 
C
 
.
 
 elegans
 
 FAIM is 50% identical to the
predicted amino acid sequence of mouse FAIM (see Fig.
2). The extensive evolutionary conservation manifest in the
sequences of human, mouse, and 
 
C
 
. elegans faim strongly
suggests that the faim gene product is a key apoptotic reg-
ulatory molecule that has been retained with minimal
change throughout phylogeny.
Discussion
Fas engagement contributes to cell fate determination in
a variety of cell types, and plays an important role in modu-
lating immune responses and regulating autoreactive B
lymphocytes (23, 42). The results reported here identify a
novel gene, isolated by differential display (28) and termed
faim, that opposes Fas-mediated apoptosis when overex-
pressed in a model B cell line, and whose expression in pri-
mary B cells is coordinately regulated with sIg signals that
block Fas killing. Thus, FAIM is an inducible effector mole-
cule that mediates Fas resistance produced in B cells by sIg
engagement, and does so by blocking a step in the Fas signal-
ing pathway before the activation of caspase 3, an effector
caspase responsible for PARP cleavage (41). The influence of
FAIM appears to be specific to Fas-induced cell death, be-
cause BAL-17 B cells stably transfected with faim are not
more resistant to apoptosis produced by staurosporine or ul-
traviolet radiation than vector-transfected controls (data not
shown). As FAIM bears no regions of homology with other
gene products that modulate Fas killing, it appears to repre-
sent a distinct new class of antiapoptotic protein.
Overexpression of FAIM in stably transfected BAL-17 B
cells produced substantial, but less than complete, resistance
against Fas-mediated apoptosis, and was less effective in
blocking Fas killing than optimal sIg signaling in primary B
cells. This suggests that receptor-mediated Fas resistance in
primary B cells cannot be explained on the basis of FAIM
induction alone. Recently we reported that Bcl-xL is in-
duced in primary B cells after sIg engagement that produces
Fas resistance, and that the Fas sensitivity of CD40L-stimu-
lated B cells from Bcl-xL overexpressing transgenic mice
was substantially reduced compared with littermate control
B cells (26). These results infer a key role for Bcl-xL in sIg-
mediated Fas resistance. However, further inhibition of
susceptibility to Fas-mediated apoptosis in Bcl-xL trans-
genic B cells was produced by anti-Ig treatment, implicat-
ing additional antiapoptotic factors (26). Thus, sIg-trig-
gered Fas resistance may result, at least in part, from the
Figure 4. Expression of faim/
FAIM in Fas-resistant primary B
cells. (A) Northern blot showing
faim gene expression in primary B
cells that were unstimulated (M),
were stimulated by CD40L alone
for 48 h (0), or were stimulated by
CD40L for 48 h plus anti-Ig
added for the last 1, 6, 18, or 48 h
of culture, as indicated. One of four comparable experiments is shown. (B) Western blot showing FAIM protein expression in primary B cells that were
stimulated by CD40L alone for 48 h (0), or were stimulated by CD40L for 48 h plus anti-Ig added for the last 6, 18, or 48 h of culture, as indicated. One
of three comparable experiments is shown. (C) Western blot showing FAIM protein expression in primary B cells from double transgenic, anti-HEL/
HEL mice that were stimulated by CD40L alone for 24 h (2), or were stimulated by CD40L in combination with either anti-Ig or sHEL, as indicated.
One of three comparable experiments is shown.954 FAIM Confers Resistance to Fas Apoptosis
combined effects of inducible FAIM and Bcl-xL expression.
In support of this, Fas-resistant faim transfectants express no
more Bcl-xL than do vector-transfected controls (data not
shown), so there is no direct linkage between FAIM and
Bcl-xL, the only other antiapoptotic gene presently impli-
cated in B cell Fas resistance. Thus, inducible resistance
against Fas is multigenic in nature. Although FAIM and
Bcl-xL may inhibit separate and distinct intracellular path-
ways leading from Fas to terminal apoptotic events (43),
the possibility that these antiapoptotic molecules interfere
with the same death mediators has not been ruled out. No-
tably, the multigenicity of inducible protection against Fas
killing suggests the intricacy of regulatory controls asserted
over apoptotic death by environmental cues.
FAIM shares no regions of homology with known anti-
apoptotic proteins and contains no known protein–protein
interaction motifs, implying that an as yet unidentified
structure is responsible for its antiapoptotic function. Pre-
liminary results suggest that the activity of this structure is
broad and crosses species boundaries, in that human HeLa
cells transiently transfected with mouse faim display Fas re-
sistance in comparison to vector-transfected controls (data
not shown). Moreover, FAIM-like genes are expressed in
other species, including C. elegans. In fact, the degree of
amino acid identity between C. elegans and mouse FAIM
(50%) is much greater than that between C. elegans ced-3
and mouse ICE, and between C. elegans ced-9 and mouse
bcl-2 (both ,25%), two pairs of genes with accepted similar
functions related to apoptosis (44, 45). This remarkably
high degree of evolutionary conservation across a broad
phylogenetic chasm suggests that FAIM plays a key role in
cellular physiology. Furthermore, three specific regions of
FAIM, encompassing 21, 17, and 17 amino acids, respec-
tively, exceed 75% identity between mouse, human, and
C. elegans FAIM; one or more of these regions may well be
indispensable to the antiapoptotic function of FAIM.
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